Your session is about to expire
← Back to Search
Cancer Vaccine
ATG-101 for Advanced Cancers (PROBE Trial)
Phase 1
Recruiting
Research Sponsored by Antengene Biologics Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Aged at least 18 years as of the date of consent.
Must not have
Radiotherapy with a wide field of radiation within 28 days.
Prior organ allograft transplantations.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year after last patient first dose
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new drug called ATG-101 on patients with advanced cancers to see if it can help treat their condition.
Who is the study for?
This trial is for adults with advanced solid tumors or mature B-cell Non-Hodgkin Lymphomas that have worsened after standard treatment, can't tolerate it, or have no suitable standard options. Participants must be expected to live at least 12 weeks and be in fairly good health (ECOG status 0-1). They should use birth control.
What is being tested?
The study tests ATG-101, a new potential cancer drug. It's the first time this drug is being tried in humans (Phase I) to see how safe it is and how well it works against certain cancers that are either spreading (metastatic) or cannot be removed by surgery.
What are the potential side effects?
Since ATG-101 is new and this is its first trial in humans, specific side effects aren't known yet. However, participants will be closely monitored for any reactions related to the immune system due to the nature of ATG-101 targeting proteins involved in cancer growth.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
I am 18 years old or older.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have not had extensive radiotherapy in the last 28 days.
Select...
I have had an organ transplant from another person.
Select...
I do not have brain tumors or cancer that has spread to my brain.
Select...
I do not have an active infection, including hepatitis B or C.
Select...
I have previously received ATG-101 or a 4-1BB agonist treatment.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ one year after last patient first dose
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year after last patient first dose
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
AEs
DLT (for Dose Escalation Phase only)
SAEs
Secondary study objectives
DCR
DOR
ORR
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Single experimental arm for ATG-101Experimental Treatment1 Intervention
Subjects with advanced or metastatic solid tumors and mature B-NHLs will be enrolled.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Non-Hodgkin's Lymphoma (NHL) include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy works by killing rapidly dividing cells, including cancer cells, but can also affect normal cells, leading to side effects.
Targeted therapies, such as monoclonal antibodies, specifically target cancer cell markers (e.g., CD20 on B-cells) to destroy malignant cells while sparing normal cells. Immunotherapy, including immune checkpoint inhibitors, enhances the body's immune response against cancer cells.
These mechanisms are crucial for NHL patients as they offer different strategies to combat the disease, potentially improving outcomes and reducing side effects. The novel agent ATG-101, being studied in clinical trials, likely involves a targeted or immunotherapeutic approach, aiming to provide a more effective and specific treatment option for patients with advanced or metastatic NHL.
Find a Location
Who is running the clinical trial?
Antengene Biologics LimitedLead Sponsor
2 Previous Clinical Trials
204 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have had allergic reactions in the past to drugs that are similar to ATG-101.I don't have any lasting side effects from previous treatments, except for hair loss.I am fully active or restricted in physically strenuous activity but can do light work.I have had cancer other than skin or cervical cancer in the last 3 years.I have not had extensive radiotherapy in the last 28 days.I have had an organ transplant from another person.My cancer has worsened despite treatment, or I can't tolerate standard treatments, and I'm expected to live at least 12 more weeks.I do not have brain tumors or cancer that has spread to my brain.I do not have an active infection, including hepatitis B or C.I do not have any uncontrolled illnesses affecting my organs or bone marrow.I haven't had cancer treatment in the last 3 weeks.I have previously received ATG-101 or a 4-1BB agonist treatment.I am 18 years old or older.I am using effective birth control methods.
Research Study Groups:
This trial has the following groups:- Group 1: Single experimental arm for ATG-101
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.